Trial reportJournal of pharmacokinetics and pharmacodynamics2019
Cabozantinib exposure-response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma.
Trial report in Journal of pharmacokinetics and pharmacodynamics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Pooled it
- A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer.Thyroid : official journal of the American Thyroid Association · 2022Trial
- Real-world clinical outcomes of cabozantinib as a second-line treatment for advanced hepatocellular carcinoma: a retrospective US claims analysis.The oncologist · 2025Article
- Optimizing Cabozantinib Dosing in Unresectable Hepatocellular Carcinoma of 7-on/7-off Regimen.Cancers · 2025Article
- Real world data of cabozantinib in patients with hepatocellular carcinoma: Focusing on dose setting and modification.Cancer medicine · 2024Article
- Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.Clinical pharmacokinetics · 2023Review
- Plasma Cabozantinib Level Measurement in Patients with Renal Cell and Hepatocellular Carcinomas Using a Simple HPLC-UV Method Suitable for Clinical Application.Current oncology (Toronto, Ont.) · 2023Article
- Population Pharmacokinetics and Exposure-Response Analysis for the Phase 3 COSMIC-311 Trial of Cabozantinib for Radioiodine-Refractory Differentiated Thyroid Cancer.Clinical pharmacokinetics · 2023Article
- Advancements in Hepatocellular Carcinoma: Potential Preclinical Drugs and their Future.Current pharmaceutical design · 2023Review
- Impact of Cabozantinib Exposure on Proteinuria and Muscle Toxicity in Patients with Unresectable Hepatocellular Carcinoma.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Precision Dosing of Targeted Therapies Is Ready for Prime Time.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- HCC and Molecular Targeting Therapies: Back to the Future.Biomedicines · 2021Review
- Advances in Liver Cancer Stem Cell Isolation and their Characterization.Stem cell reviews and reports · 2021Review
- Therapeutic drug monitoring of oral targeted antineoplastic drugs.European journal of clinical pharmacology · 2021Review
- Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options.Journal of hepatocellular carcinoma · 2021Review
- Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma.Targeted oncology · 2020Article
- Recent progress in treatment of hepatocellular carcinoma.American journal of cancer research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cabozantinib, a multi-kinase inhibitor, is approved in the United States and European Union for treatment of patients with hepatocellular carcinoma following prior sorafenib treatment. In the Phase III CELESTIAL trial, hepatocellular carcinoma patients receiving cabozantinib showed longer overall survival (OS) and progression-free survival (PFS) than those receiving placebo. The approved cabozantinib (Cabometyx
Indexed as
Identifiers
31637577What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.